BCAX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
75.7M
+26.3%
60.0M
-0.5%
60.2M
+46.5%
41.1M
+1.1%
40.7M
R&D
56.5M
+23.4%
45.8M
-3.6%
47.5M
+44.0%
33.0M
+0.0%
33.0M
SG&A
19.2M
+35.7%
14.2M
+11.3%
12.7M
+56.7%
8.1M
+5.6%
7.7M
Operating Income
-75711000
-26.3%
-59951000
+0.5%
-60242000
-46.5%
-41122000
-1.1%
-40676000
EBITDA
-75651000
-26.3%
-59907000
+0.5%
-60198000
-46.5%
-41079000
-1.1%
-40652000
Net Income
-71249000
-28.5%
-55436000
+1.4%
-56211000
-50.4%
-37386000
-2.9%
-36330000
EPS (Basic)
$-1.04
-26.8%
$-0.82
+11.8%
$-0.93
-36.8%
$-0.68
-1.5%
$-0.67
EPS (Diluted)
$-1.04
-26.8%
$-0.82
+11.8%
$-0.93
-36.8%
$-0.68
-1.5%
$-0.67
Shares (Diluted)
68.4M
+0.7%
67.9M
+11.9%
60.7M
+10.1%
55.1M
+1.1%
54.6M
Bicara Therapeutics (BCAX) — Financials